Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00851786 · ClinicalTrials.gov registry record · Phase 2
Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 395
- Enrollment target
NCT00851786 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 395 participants.
The verdict
NCT00851786, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 395 participants
- Enrollment target
Study Summary
Herpes zoster, or shingles, is the result of a viral infection that causes a painful skin rash, usually in older people or people with suppressed immune systems like those infected with HIV. The ZOSTAVAX vaccine has been shown to reduce the number of infections and symptoms of herpes zoster infection in people over the age of 60. The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of two doses of ZOSTAVAX in HIV-1-infected adults with conserved immune function (Cd4+ T cell counts \>=200 cells/uL) virologically suppressed on potent combination antiretroviral therapy (ART).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL ZOSTAVAX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 395 participants |
| Start Date | 2009-04-29 |
| Est. Completion | 2012-01-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00851786
The ClinicalTrials.gov registry entry for NCT00851786 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 395 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00851786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00851786 about?
NCT00851786 is a clinical study titled "Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy". Herpes zoster, or shingles, is the result of a viral infection that causes a painful skin rash, usually in older people or people with suppressed immune systems like those infected with HIV. The ZOSTAVAX vaccine has been shown to reduce the number of infections and symptoms of herpes zoster infectio...
What is the current status of trial NCT00851786?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 395 participants. The study started on 2009-04-29. Estimated completion is 2012-01-03.
What interventions are being tested in trial NCT00851786?
The interventions under investigation include: Placebo (BIOLOGICAL), ZOSTAVAX (BIOLOGICAL).
Who is sponsoring clinical trial NCT00851786?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.